Journal of Clinical Oncology, Vol 13, 1242-1248, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group

R Navari, D Gandara, P Hesketh, S Hall, J Mailliard, H Ritter, C Friedman and D Fitts
Simon-Williamson Clinic, Birmingham, AL 35211, USA.

PURPOSE: To compare the efficacy and safety of granisetron and ondansetron, serotonin (5-HT3) receptor antagonists shown to be effective in the prevention of chemotherapy-induced emesis. PATIENTS AND METHODS: In a double-blind, randomized, stratified, parallel-group study, the efficacy and safety of granisetron and ondansetron were compared in 987 chemotherapy-naive patients who received cisplatin in doses > or = 60 mg/m2. Granisetron was administered as a single dose of 10 or 40 micrograms/kg before the start of chemotherapy. Ondansetron was administered in doses of 0.15 mg/kg before and 4 and 8 hours after the start of chemotherapy. The three treatment groups were well-matched with respect to demographic characteristics and the dose of cisplatin administered. RESULTS: For all evaluations, single doses of granisetron 10 or 40 micrograms/kg were as effective as three 0.15-mg/kg doses of ondansetron. Total control (no vomiting, no retching, no nausea, and no use of rescue) was attained by 38%, 41%, and 39% of all patients who received granisetron 10 microgram/kg, granisetron 40 micrograms/kg, and ondansetron, respectively. No vomiting or retching and no use of rescue antiemetics were reported in 47%, 48%, and 51% of patients who received granisetron 10 micrograms/kg, granisetron 40 micrograms/kg, and ondansetron, respectively; no nausea and no use of rescue antiemetics were reported in 39%, 42%, and 40% of patients, respectively. CONCLUSION: All three treatment regimens were well-tolerated. The results of this study indicate that a single dose of granisetron 10 or 40 micrograms/kg is as effective as three doses of ondansetron 0.15 mg/kg in the prevention of nausea and vomiting induced by cisplatin chemotherapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Yonemura, N. Katsumata, H. Hashimoto, S. Satake, M. Kaneko, Y. Kobayashi, A. Takashima, Y. Kato, M. Takeuchi, Y. Fujiwara, et al. Randomized Controlled Study Comparing Two Doses of Intravenous Granisetron (1 and 3 mg) for Acute Chemotherapy-induced Nausea and Vomiting in Cancer Patients: A Non-inferiority Trial Jpn. J. Clin. Oncol., July 1, 2009; 39(7): 443 - 448. [Abstract] [Full Text] [PDF]

				D. S. Ettinger, D. K. Armstrong, S. Barbour, M. J. Berger, P. J. Bierman, B. Bradbury, G. Ellis, S. Kirkegaard, D. D. Kloth, M. G. Kris, et al. Antiemesis J Natl Compr Canc Netw, May 1, 2009; 7(5): 572 - 595. [Abstract] [PDF]

				R. McNulty Are All 5-HT3 Receptor Antagonists the Same? J Natl Compr Canc Netw, January 1, 2007; 5(1): 35 - 43. [Abstract] [PDF]

				R. M. Navari Prevention of Emesis from Multiple-Day and High-Dose Chemotherapy Regimens J Natl Compr Canc Netw, January 1, 2007; 5(1): 51 - 59. [Abstract] [PDF]

				M. Aapro Granisetron: An Update on its Clinical Use in the Management of Nausea and Vomiting Oncologist, November 1, 2004; 9(6): 673 - 686. [Abstract] [Full Text] [PDF]

				R. Gralla, M. Lichinitser, S. Van der Vegt, H. Sleeboom, J. Mezger, C. Peschel, G. Tonini, R. Labianca, A. Macciocchi, and M. Aapro Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann. Onc., October 1, 2003; 14(10): 1570 - 1577. [Abstract] [Full Text] [PDF]

				R. M Navari and J. M Koeller Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists Ann. Pharmacother., September 1, 2003; 37(9): 1276 - 1286. [Abstract] [Full Text] [PDF]

				F. M. Schnell Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control Oncologist, April 1, 2003; 8(2): 187 - 198. [Abstract] [Full Text] [PDF]

				D. Cella, K. Davis, W. Breitbart, and G. Curt Cancer-Related Fatigue: Prevalence of Proposed Diagnostic Criteria in a United States Sample of Cancer Survivors J. Clin. Oncol., July 15, 2001; 19(14): 3385 - 3391. [Abstract] [Full Text] [PDF]

				R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]

				J. I. Spector, E. P. Lester, E. M. Chevlen, D. Sciortino, J. H. Harvey, W. Whaley, S. Madajewicz, R. Isaacs, H. D. Homesley, S. Yee, et al. A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy Oncologist, December 1, 1998; 3(6): 432 - 438. [Abstract] [Full Text]